Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 10, 2020 (6 years ago)

Aripiprazole Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Labeling: Label mix up: Bottles labeled as aripiprazole 2 mg, 30 count had aripiprazole 5 mg tablets, 100 count.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Aripiprazole Tablets, USP, 2 mg, 30 Tablets per bottle, Rx only, Manufactured by: Alembic Pharmaceuticals Limited (Formulation Division) Panelav 389350, Gujarat, India Manufactured for: Alembic Pharmaceuticals, Inc. 750 Route 202, Bridgewater, NJ 08807 USA, NDC 62332-097-30.

Affected NDC 62332-0097-30

Compare with the code on your package — it is the most precise check available.

Drug: Aripiprazole

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Aripiprazole
NDC 62332-0097
2 mg/1 Tablet
Oral
Alembic Pharmaceuticals Inc. Rx
Recalling firm
Alembic Pharmaceuticals Limited
NDC code
62332-097-30
Origin
N/A, India
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1341-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Aripiprazole recalls

See all
Class II · Moderate risk

Aripiprazole Tablets USP

Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg.

Ongoing Labeling / mix-up Ajanta Pharma USA Inc NDC 27241-056-03 D-0594-2026
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-011-13 D-0469-2024
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-009-13 D-0468-2024
Class III · Low risk

Abilify (aripiprazole)

Cross Contamination with Other Products

Ongoing Cross-contamination Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd. NDC 59148-008-13 D-0467-2024

Other recalls by Alembic Pharmaceuticals Limited

All 2020 recalls
Class II · Moderate risk

Bromfenac Ophthalmic Solution 0.07%

Failed Impurities/Degradation Specifications: out of specification at the time of testing i.e. 20th month stability testing.

Ongoing Impurity / degradation Alembic Pharmaceuticals, INC. NDC 62332-583-03 Recall number pending
Class III · Low risk

Fesoterodine Fumarate

Failed Impurities/Degradation Specifications: Due to levels of 'Diester Impurity' exceeding the specification limit.

Ongoing Impurity / degradation Alembic Pharmaceuticals Limited NDC 62332-176-30 D-0248-2026
Class III · Low risk

Fesoterodine Fumarate

Failed Impurities/Degradation Specifications: Due to levels of 'Diester Impurity' exceeding the specification limit.

Ongoing Impurity / degradation Alembic Pharmaceuticals Limited NDC 62332-175-30 D-0156-2026
Class II · Moderate risk

Doxepin Hydrochloride Capsules

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Ongoing Nitrosamine impurity Alembic Pharmaceuticals Limited NDC 62332-637-31 D-0566-2025